E&Y: Data analysis key to reimbursement risk management

Drug companies need new proficiencies in data analysis to offset the risks to reimbursement. The risks arise from pharma's loss of exclusive control over outcomes data, says Ernst & Young in its 82-page Progressions: Pharma 3.0 report.

Health IT and healthcare reform are dealing a one-two punch to existing pharma strategies, according to the consultancy. Personal health records, smart phone applications, and other technologies give patients a bigger role in managing their healthcare at the same time that government and payers are providing incentives for them to become more involved.

Pharma companies need to get in step with hospitals and payers, which are now mining electronic health records for correlations between prescribing patterns and patient outcomes. And they must adopt a health-outcomes delivery business model in place of the existing drug-development model.

- see the release
- here's the sign-up form for the free report

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.